{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:04:00Z","timestamp":1791299040345,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,31]]},"DOI":"10.7759\/cureus.109979","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T16:21:15Z","timestamp":1780244475000},"source":"Crossref","is-referenced-by-count":1,"title":["Beyond Endoscopy: A Narrative Review of the Emerging Role of Gastroenterologists in Obesity Medicine, GLP-1 (Glucagon-Like Peptide-1) Therapy, and Metabolic Care"],"prefix":"10.7759","author":[{"given":"Mohammad","family":"Alali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Kunwer","family":"Naveed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Alnounou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Alharami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bola","family":"Nashed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organization. Obesity and overweight. (2024). Accessed: May 11, 2026: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell EE","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021, 397:2212-24. 10.1016\/S0140-6736(20)32511-3","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi ZM","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023, 77:1335-47. 10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.12.052","article-title":"Gastrointestinal complications of obesity","volume":"152","author":"Camilleri M","year":"2017","unstructured":"Camilleri M, Malhi H, Acosta A. Gastrointestinal complications of obesity. Gastroenterology. 2017, 152:1656-70. 10.1053\/j.gastro.2016.12.052","journal-title":"Gastroenterology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.01.035","article-title":"Clinical practice update: expert review on endoscopic bariatric\u00a0therapies","volume":"152","author":"Abu Dayyeh BK","year":"2017","unstructured":"Abu Dayyeh BK, Edmundowicz S, Thompson CC. Clinical practice update: expert review on endoscopic bariatric\u00a0therapies. Gastroenterology. 2017, 152:716-29. 10.1053\/j.gastro.2017.01.035","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al.. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023, 78:1966-86. 10.1097\/HEP.0000000000000520","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez M","year":"2017","unstructured":"Romero-G\u00f3mez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017, 67:829-46. 10.1016\/j.jhep.2017.05.016","journal-title":"J Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.41703.x","article-title":"Obesity is an independent risk factor for GERD symptoms and erosive esophagitis","volume":"100","author":"El-Serag HB","year":"2005","unstructured":"El-Serag HB, Graham DY, Satia JA, Rabeneck L. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol. 2005, 100:1243-50. 10.1111\/j.1572-0241.2005.41703.x","journal-title":"Am J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-304701","article-title":"Obesity and colorectal cancer","volume":"62","author":"Bardou M","year":"2013","unstructured":"Bardou M, Barkun AN, Martel M. Obesity and colorectal cancer. Gut. 2013, 62:933-47. 10.1136\/gutjnl-2013-304701","journal-title":"Gut"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-0433-9","article-title":"Gut microbiota in human metabolic health and disease","volume":"19","author":"Fan Y","year":"2021","unstructured":"Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021, 19:55-71. 10.1038\/s41579-020-0433-9","journal-title":"Nat Rev Microbiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne LJ","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025, 393:26-36. 10.1056\/NEJMoa2416394","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff AM","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023, 389:2221-32. 10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0566","article-title":"Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes?","volume":"181","author":"Nauck MA","year":"2019","unstructured":"Nauck MA, Meier JJ. Management of endocrine disease: are all GLP-1 agonists equal in the treatment of type 2 diabetes?. Eur J Endocrinol. 2019, 181:R211-34. 10.1530\/EJE-19-0566","journal-title":"Eur J Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00188-2","article-title":"Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions","volume":"9","author":"Jalleh RJ","year":"2024","unstructured":"Jalleh RJ, Rayner CK, Hausken T, Jones KL, Camilleri M, Horowitz M. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. Lancet Gastroenterol Hepatol. 2024, 9:957-64. 10.1016\/S2468-1253(24)00188-2","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.10.003","article-title":"Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period","volume":"23","author":"Kindel TL","year":"2025","unstructured":"Kindel TL, Wang AY, Wadhwa A, et al.. Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Clin Gastroenterol Hepatol. 2025, 23:2083-5. 10.1016\/j.cgh.2024.10.003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis","volume":"387","author":"Armstrong MJ","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al.. Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis. Lancet. 2016, 387:679-90. 10.1016\/S0140-6736(15)00803-X","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal AJ","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al.. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025, 392:2089-99. 10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic V","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al.. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024, 391:109-21. 10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.12.030","article-title":"Endoscopic sleeve gastroplasty alters gastric physiology and induces loss of body weight in obese individuals","volume":"15","author":"Abu Dayyeh BK","year":"2017","unstructured":"Abu Dayyeh BK, Acosta A, Camilleri M, Mundi MS, Rajan E, Topazian MD, Gostout CJ. Endoscopic sleeve gastroplasty alters gastric physiology and induces loss of body weight in obese individuals. Clin Gastroenterol Hepatol. 2017, 15:37-43.e1. 10.1016\/j.cgh.2015.12.030","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2015.06.038","article-title":"ASGE position statement on endoscopic bariatric therapies in clinical practice","volume":"82","author":"Sullivan S","year":"2015","unstructured":"Sullivan S, Kumar N, Edmundowicz SA, Abu Dayyeh BK, Jonnalagadda SS, Larsen M, Thompson CC. ASGE position statement on endoscopic bariatric therapies in clinical practice. Gastrointest Endosc. 2015, 82:767-72. 10.1016\/j.gie.2015.06.038","journal-title":"Gastrointest Endosc"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.6221","article-title":"Semaglutide vs endoscopic sleeve gastroplasty for weight loss","volume":"7","author":"Haseeb M","year":"2024","unstructured":"Haseeb M, Chhatwal J, Xiao J, Jirapinyo P, Thompson CC. Semaglutide vs endoscopic sleeve gastroplasty for weight loss. JAMA Netw Open. 2024, 7:e246221. 10.1001\/jamanetworkopen.2024.6221","journal-title":"JAMA Netw Open"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez E","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al.. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015, 149:367-78.e5; quiz e14-5. 10.1053\/j.gastro.2015.04.005","journal-title":"Gastroenterology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients","volume":"149","author":"Lassailly G","year":"2015","unstructured":"Lassailly G, Caiazzo R, Buob D, et al.. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015, 149:379-88; quiz e15-6. 10.1053\/j.gastro.2015.04.014","journal-title":"Gastroenterology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison SA","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, et al.. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024, 390:497-509. 10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.10.023","article-title":"White paper AGA: POWER - practice guide on obesity and\u00a0weight management, education, and resources","volume":"15","author":"Acosta A","year":"2017","unstructured":"Acosta A, Streett S, Kroh MD, et al.. White paper AGA: POWER - practice guide on obesity and\u00a0weight management, education, and resources. Clin Gastroenterol Hepatol. 2017, 15:631-49.e10. 10.1016\/j.cgh.2016.10.023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.gande.2026.02.003","article-title":"Current evidence and emerging role of endoscopic bariatric and metabolic therapies in gastrointestinal endoscopy","volume":"4","author":"Korram P","year":"2026","unstructured":"Korram P, Sahu P, Satapathy T. Current evidence and emerging role of endoscopic bariatric and metabolic therapies in gastrointestinal endoscopy. Gastroenterol Endosc. 2026, 4:100-16. 10.1016\/j.gande.2026.02.003","journal-title":"Gastroenterol Endosc"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino D","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, et al.. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021, 325:1414-25. 10.1001\/jama.2021.3224","journal-title":"JAMA"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.5946\/ce.2018.148","article-title":"Training in bariatric and metabolic endoscopic therapies","volume":"51","author":"Jirapinyo P","year":"2018","unstructured":"Jirapinyo P, Thompson CC. Training in bariatric and metabolic endoscopic therapies. Clin Endosc. 2018, 51:430-8. 10.5946\/ce.2018.148","journal-title":"Clin Endosc"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22054","article-title":"Perceptions of barriers to effective obesity care: results from the national ACTION study","volume":"26","author":"Kaplan LM","year":"2018","unstructured":"Kaplan LM, Golden A, Jinnett K, et al.. Perceptions of barriers to effective obesity care: results from the national ACTION study. Obesity (Silver Spring). 2018, 26:61-9. 10.1002\/oby.22054","journal-title":"Obesity (Silver Spring)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/496709-beyond-endoscopy-a-narrative-review-of-the-emerging-role-of-gastroenterologists-in-obesity-medicine-glp-1-glucagon-like-peptide-1-therapy-and-metabolic-care","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T16:21:16Z","timestamp":1780244476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/496709-beyond-endoscopy-a-narrative-review-of-the-emerging-role-of-gastroenterologists-in-obesity-medicine-glp-1-glucagon-like-peptide-1-therapy-and-metabolic-care"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.109979","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,31]]}}}